Novo Nordisk remains a strong buy due to robust volume growth in its GLP-1 products despite recent earnings misses and price pressure. The oral version of Wegovy exceeded expectations with strong unit economics and a global rollout that supports future volume and margin growth. Key upcoming catalysts include Medicare coverage for Wegovy, international launches, and pipeline advancements like CagriSema and the REIMAGINE program. The stock trades at a significant discount to peers, with a scenario analysis suggesting a 53.4% upside to a $64.41 price target.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
